ClinicalTrials.gg
Not yet recruitingNCT07937579Updated Nov 16, 2026

Efficacy and Safety of High-Flow Nasal Cannula During Transcatheter Closure Procedures

An interventional study of High-flow nasal cannula and Conventional nasal cannula in Congenital Heart Disease and High Flow Nasal Canula, sponsored by Fu Jen Catholic University. Not yet recruiting at 2 sites in Taiwan. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Fu Jen Catholic University · Not applicable, Interventional, and Supportive care

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
6 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Heart Defects, Congenital with a site in Taiwan — 2 open to participants now, 4 under way, none of them phase 3. Heart Defects, Congenital · Taiwan.

Started
2026
with 1 other
No phase
6 of 12
2 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Fu Jen Catholic University

Among the 12 studies in Heart Defects, Congenital with a site in Taiwan, this one is one of 2 that started in 2026, is one of 6 with no phase, and was the 12th registered.

Heart Defects, Congenital

992 studies on the registry are indexed under Heart Defects, Congenital; 251 are open to participants now.

Browse Heart Defects, Congenital studies →

Open to participants now

2 of the 12 studies in Heart Defects, Congenital with a site in Taiwan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 154 Heart Defects, Congenital studies recruiting now, 67 (44%) set no upper age limit and 79 (51%) stop at 75 or younger; 110 take children under 18; 25 take healthy volunteers.

This study: 6 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Heart Defects, Congenital with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of high-flow nasal cannula oxygen therapy, compared with standard nasal cannula oxygen therapy, as respiratory support during transcatheter closure procedures for congenital heart disease under non-intubated deep sedation.

Read the detailed description

Transcatheter closure is a standard treatment for selected congenital heart diseases and is often performed under deep sedation with transesophageal echocardiographic guidance. During non-intubated sedation, oxygen desaturation may occur due to airway collapse, respiratory depression, supine positioning, or limited cardiopulmonary reserve. Standard nasal cannula oxygen may be insufficient in high-risk patients, whereas HFNC provides heated, humidified high-flow oxygen, stable FiO2, dead-space washout, and mild positive airway pressure to improve oxygenation and airway stability. This study will enroll pediatric and adult patients undergoing transcatheter closure for congenital heart disease. Participants will be stratified by age and/or clinical risk and randomized to receive either HFNC or standard nasal cannula oxygen therapy. This study is expected to clarify whether HFNC can reduce intra-procedural oxygen desaturation, improve oxygenation stability, decrease emergency airway interventions, and maintain hemodynamic safety during deep sedation. The findings may support standardized respiratory support protocols in cardiac catheterization laboratories and provide evidence for individualized peri-procedural care in pediatric and adult congenital heart disease patients.

03

Conditions studied

  • Congenital Heart Disease
  • High Flow Nasal Canula

Keywords

  • High flow nasal cannula
  • Congenital heart disease
  • Transcatheter closure
  • Cardiac catheterization
  • Oxygen desaturation
  • Deep sedation
  • Respiratory support
  • Noninvasive cardiac output monitoring
  • Hemodynamics
04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with a simple congenital heart defect, including an atrial septal defect, ventricular septal defect, patent ductus arteriosus, or patent foramen ovale, and scheduled for an elective transcatheter closure procedure.
  • physical status classification I-III.
  • Written .

Exclusion criteria

Exclusion Criteria:

  • Complex congenital heart disease.
  • Severe anatomical abnormalities of the upper airway.
  • Preprocedural severe cyanosis or hypoxemia, defined as an oxygen saturation below 90% while room air.
  • A to high-flow nasal cannula, as determined by the physician.
  • A skin condition over the chest that prevents placement of electrodes for noninvasive cardiac output monitoring.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    High-flow nasal cannula group

    Receive high-flow nasal cannula during transcatheter closure procedures under deep sedation

    Device: High-flow nasal cannula

  • Active comparator
    Conventional nasal cannula oxygen therapy

    Receive conventional nasal cannula oxygen therapy during transcatheter closure procedures under deep sedation

    Device: Conventional nasal cannula

Interventions

  • DeviceHigh-flow nasal cannula

    Heated, humidified high-flow oxygen will be delivered through a nasal cannula.

  • DeviceConventional nasal cannula

    Oxygen will be delivered through a nasal cannula.

06

What researchers measure

Primary outcomes

  1. Incidence of hypoxemia

    Defined as at least one episode of peripheral oxygen saturation below 90% lasting at least 10 seconds

    Time frame: From initiation of the assigned oxygen therapy to completion of transcatheter closure procedure

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2027, 7 months later.

Of 205 non-industry interventional studies with no phase under Heart Defects, Congenital, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 7 months is below that.

Counting every sponsor, half of 223 studies reached it within 34 months; a quarter within 17 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937579
Lead sponsor
Fu Jen Catholic University
Responsible party
Ke-Yun, Chao (Assistant Professor, Fu Jen Catholic University) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Ke-Yun Chao, PhD
Contact
148540@mail.fju.edu.tw
+886905301879
Ke-Yun Chao, PhD
principal investigator · Fu Jen Catholic University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion